Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Clinical trial designs & ESMO-MCBS

Bishal Gyawali • 17 Sep 2020
ESMO 2020
General

Bishal Gyawali, MD, PhD, Queen’s University, Kingston, ON, Canada, discusses the flaws in clinical trial designs that can skew the European Society of Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). The ESMO-MCBS is a standardized, validated tool to assess the clinical benefit from anticancer therapies in clinical trials. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Bishal Gyawali

4:16
Gender differences in outcomes of cancer patients with COVID-19
Bishal Gyawali • 17 Sep 2020

Related Videos

1:56
Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumors
Haeseong Park • 8 Apr 2024
2:45
Remaining challenges in treating solid tumors with CAR-Treg therapy
Leonardo Ferreira • 8 Apr 2024
2:01
Engineering chimeric antigen receptor regulatory T cells for treating cancer
Leonardo Ferreira • 8 Apr 2024
0:59
What challenges are there in using CAR-T cells for solid tumors?
Leonardo Ferreira • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals